<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958109</url>
  </required_header>
  <id_info>
    <org_study_id>267339</org_study_id>
    <nct_id>NCT04958109</nct_id>
  </id_info>
  <brief_title>Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test</brief_title>
  <official_title>Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to understand how exogenous kisspeptin affects metabolism by&#xD;
      evaluating responses to an oral glucose tolerance test&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assignment: Each study subject will serve as their own control. The order of the visits will&#xD;
      be randomized.&#xD;
&#xD;
      Delivery of Interventions:&#xD;
&#xD;
        -  Prior to the study visit, subjects will undergo a review of their medical history and&#xD;
           screening laboratories.&#xD;
&#xD;
        -  During the inpatient study, the subjects will&#xD;
&#xD;
             -  Undergo a 16-hour kisspeptin infusion&#xD;
&#xD;
             -  Undergo an oral glucose tolerance test&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Difference in Oral glucose Sensitivity Index (Kisspeptin-Placebo)</measure>
    <time_frame>2 hours</time_frame>
    <description>Change in Oral glucose Sensitivity Index between kisspeptin and placebo arms in OGTT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>Kisspeptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Intravenous administration of kisspeptin 112-121 x 16 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>• Intravenous administration of placebo x 16 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test</intervention_name>
    <description>Administration of a 75 gm oral glucose tolerance test</description>
    <arm_group_label>Kisspeptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kisspeptin</intervention_name>
    <description>Intravenous administration of kisspeptin 112-121 x 16 hours</description>
    <arm_group_label>Kisspeptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous administration of Placebo 16 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        History:&#xD;
&#xD;
          -  over the age of 18,&#xD;
&#xD;
          -  normal pubertal development&#xD;
&#xD;
          -  stable weight for previous three months,&#xD;
&#xD;
          -  normal body mass index (BMI between 18.5-25)&#xD;
&#xD;
          -  regular menstrual cycles&#xD;
&#xD;
        Physical examination:&#xD;
&#xD;
        • systolic BP &lt; 140 mm Hg, diastolic &lt; 90 mm Hg&#xD;
&#xD;
        Laboratory studies: (per MGH reference ranges)&#xD;
&#xD;
          -  normal hemoglobin&#xD;
&#xD;
          -  hemoglobin A1C &lt; 6.5%&#xD;
&#xD;
          -  BUN, creatinine not elevated&#xD;
&#xD;
          -  AST, ALT &lt; 3x upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active illicit drug use,&#xD;
&#xD;
          -  history of a medication reaction requiring emergency medical care,&#xD;
&#xD;
          -  difficulty with blood draws.&#xD;
&#xD;
          -  history of chronic disease, except well controlled thyroid disease,&#xD;
&#xD;
          -  recent use of prescription medications which interfere with metabolism or reproduction&#xD;
             (recent = within 5 half-lives of the drug). Use of levothyroxine or seasonal allergy&#xD;
             medications is acceptable,&#xD;
&#xD;
          -  history of diabetes in a first degree relative,&#xD;
&#xD;
          -  use of contraceptive pills, patches or vaginal rings within last 4 weeks.&#xD;
&#xD;
          -  hyperlipidemia by fasting lipid panel&#xD;
&#xD;
          -  positive serum pregnancy test (for all women)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Lippincott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Lippincott, MD</last_name>
    <phone>617-726-8434</phone>
    <email>MGHKisspeptinResearch@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Lippincott, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, Harvard Reproductive Endocrine Sciences Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

